Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety

Pharmacological Research

Volumn 59, Issue 3, 2009, Pages 135-153

  Savarino, Vincenzo ^a   Di Mario, Francesco ^b   Scarpignato, Carmelo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Acid secretion; Esomeprazole; GORD; Heartburn; Lansoprazole; Omeprazole; Pantoprazole; Proton pump inhibitors; Rabeprazole; Safety; Side effects

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIVITAMIN K; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CHROMOGRANIN A; CISAPRIDE; DICLOFENAC; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; METRONIDAZOLE; NON PRESCRIPTION DRUG; OMEPRAZOLE; PANTOPRAZOLE; PEPSINOGEN I; PHENYTOIN; PICOPRAZOLE; PROTON PUMP; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE; TIMOPRAZOLE;

ABDOMINAL PAIN; ACHLORHYDRIA; ACUTE PANCREATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BARRETT ESOPHAGUS; BEDTIME DOSAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLLAGENOUS COLITIS; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DYSPEPSIA; EPITHELIUM DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HIP FRACTURE; HUMAN; HYPERGASTRINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; INTERSTITIAL NEPHRITIS; INTESTINE INFECTION; KIDNEY FAILURE; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPHOCYTIC COLITIS; MICROSCOPIC COLITIS; MUSCLE CRAMP; MYOPATHY; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PHARYNGITIS; POLYMYOSITIS; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RESPIRATORY TRACT INFECTION; REVIEW; RHABDOMYOLYSIS; RHINITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SODIUM BLOOD LEVEL; STOMACH ACID SECRETION; STOMACH PH; STOMACH POLYP; SYMPTOM; TERATOGENICITY; UNSPECIFIED SIDE EFFECT;

ABSORPTION; DRUG INTERACTIONS; GASTRIC ACID; GASTRINS; GASTROESOPHAGEAL REFLUX; HEART; HIP FRACTURES; HUMANS; PANCREATITIS; PNEUMONIA; PROTON PUMP INHIBITORS; TREATMENT FAILURE;

EID: 59349084436     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.09.016     Document Type: Review

References (249)

1. Hersey S.J., and Sachs G. Gastric acid secretion. Physiol Rev 75 (1995) 155-189
2. Aihara T., Nakamura E., Amagase K., Tomita K., Fujishita T., Furutani K., et al. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future. Pharmacol Ther 98 (2003) 109-127
3. Lindstrom E., Chen D., Norlen P., Andersson K., and Hakanson R. Control of gastric acid secretion: the gastrin-ECL cell-parietal cell axis. Comp Biochem Physiol A Mol Integr Physiol 128 (2001) 505-514
4. +-ATPase: structure, function, and inhibition. Pflugers Arch; in press.
5. Makhlouf G.M., and Schubert M.L. Gastric somatostatin: a paracrine regulator of acid secretion. Metabolism 39 Suppl. 2 (1990) 138-142
6. Chey W.Y., and Chang T.M. Neural control of the release and action of secretin. J Physiol Pharmacol 54 Suppl. 4 (2003) 105-112
7. Olbe L., Carlsson E., and Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2 (2003) 132-139
8. Stedman C.A.M., and Barclay M.L. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14 (2000) 963-978
9. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 17 (1997) 22-37
10. Kromer W. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. Scand J Gastroenterol 36 Suppl. 234 (2001) 3-9
11. +-ATPase. Annu Rev Pharmacol Toxicol 35 (1995) 277-305
12. 2-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 15 (2001) 355-370
13. Hatlebakk J.G., Katz P.O., Camacho-Lobato L., and Castell D.O. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 14 (2000) 1267-1272
14. 2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 9 Suppl. 1 (1995) 9-14
15. 2 de l'histamine. Gastroenterol Clin Biol 23 (1999) S78-S89
16. 2-receptor antagonists. An overview. Scand J Gastroenterol 27 Suppl. 193 (1992) 14-19
17. Haney S., and Hancox R.J. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 99 (2005) 566-571
18. DuPen A., Shen D., and Ersek M. Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manag Nurs 8 (2007) 113-121
19. Lachman L., and Howden C.W. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 95 (2000) 57-61
20. 2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease. J Gastroenterol Hepatol 21 (2006) 1581-1585
21. Sandvik A.K., Brenna E., and Waldum H.L. Review article: the pharmacological inhibition of gastric acid secretion: tolerance and rebound. Aliment Pharmacol Ther 11 (1997) 1013-1018
22. Scarpignato C. Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle. Dig Liver Dis 37 (2005) 468-474
23. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122 (2002) 625-632
24. Rackoff A., Agrawal A., Hila A., Mainie I., Tutuian R., and Castell D.O. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 18 (2005) 370-373
25. 2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 15 (2000) 1291-1299
26. 2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 21 (2005) 1299-1312
27. Earnest D., Robinson M., Rodriguez-Stanley S., Ciociola A.A., Jaffe P., Silver M.T., et al. Managing heartburn at the 'base' of the GERD 'iceberg': effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther 14 (2000) 911-918
28. Robinson M., Rodriguez-Stanley S., Ciociola A.A., Filinto J., Zubaidi S., Miner Jr. P.B., et al. Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced heartburn. Aliment Pharmacol Ther 15 (2001) 1365-1374
29. Peghini P.L., Katz P.O., Bracy N.A., and Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 9 (1998) 763-767
30. 2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 15 (2001) 1351-1356
31. Cross L.B., and Justice L.N. Combination drug therapy for gastroesophageal reflux disease. Ann Pharmacother 36 (2002) 912-916
32. 2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 4 (2004) CD004275
33. Vakil N., Guda N., and Partington S. The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy. Aliment Pharmacol Ther 23 (2006) 649-653
34. Orr W.C. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 17 (2005) 113-120
35. Scarpignato C., and Hunt R.H. Proton pump inhibitors: the beginning of the end or the end of the beginning?. Curr Opin Pharmacol 8 (2008) 677-684
36. Tutuian R., Katz P.O., and Castell D.O. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 16 (2004) 441-443
37. Katz P.O., and Tutuian R. Histamine receptor antagonists, proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol 15 (2001) 371-384
38. McColl K.E.L., and Kennerley P. Proton pump inhibitors-differences emerge in the hepatic metabolism. Dig Liver Dis 34 (2002) 461-467
39. Thomson A.B.R. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2 (2000) 482-493
40. Langman M.J.S. Which PPI?. Gut 49 (2001) 309-310
41. Kromer W., Horbach S., and Lühmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 59 (1999) 57-77
42. Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. NICE, UK: Technology Appraisal Guidance No. 7 [http://www.NICE.org.uk/]; 2000.
43. Pantoflickova D., Dorta G., Ravic M., Jornod P., and Blum A.L. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 17 (2003) 1507-1514
44. Tonini M., Vigneri S., Savarino V., and Scarpignato C. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig Liver Dis 33 (2001) 600-606
45. Robinson M. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment Pharmacol Ther 20 Suppl. 6 (2004) 30-37
46. Adachi K., Hashimoto T., Hamamoto N., Hirakawa K., Niigaki M., Miyake T., et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 18 (2003) 1392-1398
47. Pace F., Tonini M., Pallotta S., Molteni P., and Porro G.B. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther 26 (2007) 195-204
48. Metz D.C., Inadomi J.M., Howden C.W., van Zanten S.J., and Bytzer P. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 102 (2007) 642-653
49. Lim P.W., Goh K.L., and Wong B.C. CYP2C19 genotype and the PPIs-focus on rabeprazole. J Gastroenterol Hepatol 20 Suppl. (2005) S22-S28
50. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44 (2006) 297-302
51. Blume H., Donath F., Warnke A., and Schug B.S. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 29 (2006) 769-784
52. Vakil N., van Zanten S.V., Kahrilas P., Dent J., Jones R., and Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101 (2006) 1900-1920
53. Galmiche J.P., Letessier E., and Scarpignato C. Treatment of gastro-oesophageal reflux disease in adults. Br Med J 316 (1998) 1720-1723
54. Pace F., Sonnenberg A., and Bianchi Porro G. The lessons learned from randomized clinical trials of GERD. Dig Liver Dis 39 (2007) 993-1000
55. Vela M.F. Empiric PPI therapy or endoscopy for the initial management of patients with GERD in the absence of alarm features?. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 548-549
56. Dent J. Quadriennal review-gastro-oesophageal reflux disease. Digestion 59 (1998) 433-445
57. Scarpignato C. Gastric emptying in gastroesophageal reflux disease and other functional esophageal disorders. Front Gastrointest Res 22 (1994) 223-259
58. Emerenziani S., and Sifrim D. Gastroesophageal reflux and gastric emptying, revisited. Curr Gastroenterol Rep 7 (2005) 190-195
59. Savarino V., and Dulbecco P. Optimizing symptom relief and preventing complications in adults with gastro-oesophageal reflux disease. Digestion 69 Suppl. 1 (2004) 9-16
60. De Caestecker J.S., Blackwell J.N., Pryde A., and Heading R.C. Daytime gastro-oesophageal reflux is important in oesophagitis. Gut 28 (1987) 519-526
61. Scarpignato C., Pelosini I., and Contini S. How abnormal is gastric function in patients with Barrett's esophagus?. In: Giuli R., Siewert J.R., Couturier D., and Scarpignato C. (Eds). Barrett's Esophagus. 250 Questions, 250 Answers vol. 1 (2003), John Libbey Eurotext, Paris 26-34
62. Savarino V., Mela G.S., Zentilin P., Bisso G., Pivari M., Vigneri S., et al. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther 12 (1998) 1241-1247
63. Chiba N., De Gara C.J., Wilkinson J.M., and Hunt R.H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112 (1997) 1798-1810
64. 2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 11 (2005) 4067-4077
65. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev (2006) 3 CD002095
66. Khan M., Santana J., Donnellan C., Preston C., and Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev (2007) 2 CD003244
67. Bell N.J.V., Burget D.W., Howden C.W., Wilkinson J., and Hunt R.H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51 Suppl. 1 (1992) 59-67
68. Yuan Y., Thabane M., and Hunt R.H. Does suppression of 24-h intragastric pH predict healing of erosive esophagitis with antisecretory treatment? A meta-analysis. Gastroenterology 132 Suppl. 2 (2007) A489
69. Katz P.O., Ginsberg G.G., Hoyle P.E., Sostek M.B., Monyak J.T., and Silberg D.G. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 25 (2007) 617-628
70. Vakil N., and Fennerty M.B. Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 18 (2003) 559-568
71. Gralnek I.M., Dulai G.S., Fennerty M.B., and Spiegel B.M.R. Esomeprazole versus other proton pump inhibitors in erosive esophagistis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 4 (2006) 1452-1458
72. Edwards S.J., Lind T., and Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis-a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 24 (2006) 743-750
73. Dekkers C.P., Beker J.A., Thjodleifsson B., Gabryelewicz A., Bell N.E., and Humphries T.J. Double-blind placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 13 (1999) 49-57
74. Holtmann G., Bytzer P., Metz M., Loeffler V., and Blum A.L. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 16 (2002) 479-485
75. Robinson M., Fitzgerald S., Hegedus R., Murthy A., Jokubaitis L, and On behalf of the FAST trial investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 16 (2002) 445-454
76. Richter J.E., Kahrilas P.J., Johanson J., Maton P., Breiter J.R., Hwang C., et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 96 (2001) 656-665
77. Miner P., Orr W., Filippone J., Jokubaitis L., and Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 97 (2002) 1332-1339
78. Farup C., Kleinman L., Sloan S., Ganoczy D., Chee E., Lee C., et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease in health-related quality of life. Arch Intern Med 161 (2001) 45-52
79. Mathias S.D., Colwell H.H., Miller D.P., Pasta D.J., Henning J.M., and Ofman J.J. Health-related quality of life and quality-days incrementally gained in symptomatic non-erosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci 46 (2001) 2416-2423
80. Johnson D.A., Orr W.C., Crawley J.A., Traxler B., McCullough J., Brown K.A., et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 100 (2005) 1914-1922
81. Shaheen N.J., Madanick R.D., Alattar M., Morgan D.R., Davis P.H., Galanko J.A., et al. Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy. Dig Dis Sci 53 (2008) 1493-1499
82. Zentilin P., Savarino V., Mastracci L., Spaggiari P., Dulbecco P., Ceppa P., et al. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol 100 (2005) 2299-2306
83. Quigley E.M. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities?. Best Pract Res Clin Gastroenterol 18 (2004) 695-706
84. Neumann H., Monkemuller K., Kandulski A., and Malfertheiner P. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett's esophagus. Dig Dis 26 (2008) 243-247
85. Dean B.B., Gano A.D., Knight K., Ofman J.J., and Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2 (2004) 656-664
86. Frazzoni M., Manno M., De Micheli E., and Savarino V. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?. Dig Liver Dis 38 (2006) 643-648
87. Shi G., Bruley des Varannes S., Scarpignato C., Le Rhun M., and Galmiche J.P. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 37 (1995) 457-464
88. Watson R.G., Tham T.C., Johnston B.T., and McDougall N.I. Double-blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux-the "sensitive oesophagus". Gut 40 (1997) 587-590
89. Galmiche J.P., Clouse R.E., Bálint A., Cook I.J., Kahrilas P.J., Paterson W.G., et al. Functional esophageal disorders. Gastroenterology 130 (2006) 1459-1465
90. Carlsson R., Dent J., Watts R., Riley S., Sheikh R., Hatlebakk J., et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10 (1998) 119-124
91. Donnellan C., Sharma N., Preston C., and Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2 (2005) CD003245
92. Edwards S.J., Lind T., and Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. J Outcomes Res 6 (2002) 1-14
93. Davidson R.A. Does it work or not? Clinical vs statistical significance. Chest 106 (1994) 932-934
94. Lauritsen K., Devière J., Bigard M.A., Bayerdörffer E., Mózsik G., Murray F., et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 17 (2003) 333-341
95. Vigneri S., Termini R., Leandro G., Badalamenti S., Pantalena M., Savarino V., et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333 (1995) 1106-1110
96. Robinson M., Lanza F., Avner D., and Haber N. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 124 (1996) 859-867
97. Caos A., Moskovitz M., Dayal Y., Perdomo C., Niecestro R., and Barth J. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rabeprazole Study Group. Am J Gastroenterol 95 (2000) 3081-3088
98. Thjodleifsson B., Rindi G., Fiocca R., Humphries T.J., Morocutti A., Miller N., et al. A randomized, double-blind trial of the efficacy and safety of 10 and 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 17 (2003) 343-351
99. Caos A., Breiter J., Perdomo C., and Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 and 20 mg vs placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther 22 (2005) 193-202
100. Talley N.J., Lauritsen K., Tunturi-Hihnala H., Lind T., Moum B., Bang C., et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of "on demand" therapy for 6 months. Aliment Pharmacol Ther 15 (2001) 347-354
101. Kaspari S., Kupcinskas L., Heinze H., and Berghofer P. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 17 (2005) 935-941
102. Scholten T., Dekkers C.P., Schütze K., Körner T., Bohuschke M., and Gatz G. On demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD. The ORION study. Digestion 72 (2005) 76-85
103. Tsai H.H., Chapman R., Shepherd A., McKeith D., Anderson M., Vearer D., et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study. Aliment Pharmacol Ther 15 (2004) 657-665
104. Bour B., Staub J.L., Chousterman M., Labayle D., Nalet B., Nouel O., et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole "on-demand" treatment compared with continuous treatment. Aliment Pharmacol Ther 21 (2005) 805-812
105. Bytzer P., Blum A.L., De Herdt D., and Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 20 (2004) 181-188
106. Johnsson F., Moum B., Vilien M., Grove O., Simrén M., and Thoring M. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 37 (2002) 642-647
107. Sjöstedt S., Befrits R., Sylvan A., Harthon C., Jörgensen L., Carling L., et al. Daily treatment with esomeprazole is superior to that taken on-demand for mantenance of healed erosive oesophagitis. Aliment Pharmacol Ther 22 (2005) 183-191
108. Smith P.M., Kerr G.D., Cockel R., Ross B.A., Bate C.M., Brown P., et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign oesophageal stricture. Restore Investigator Group. Gastroenterology 107 (1994) 1312-1318
109. Swarbrick E.T., Gough A.L., Foster C.S., Christian J., Garrett A.D., and Langworthy C.H. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol 8 (1996) 431-438
110. Ruigomez A., Garcia Rodriguez L.A., Wallander M.-A., Johansson S., and Eklund S. Esophageal stricture: incidence, treatment patterns and recurrence rate. Am J Gastroenterol 101 (2006) 2685-2692
111. 2 receptor antagonist and proton pump inhibitor era. Dig Liver Dis 35 (2003) 143-150
112. Guda N.M., and Vakil N. Proton pump inhibitors and the time trends for esophageal dilation. Am J Gastroenterol 99 (2004) 797-800
113. El-Serag H.B., and Lau M. Temporal trends in new and recurrent oesophageal strictures in a Medicare population. Aliment Pharmacol Ther 25 (2007) 1223-1229
114. Spechler S.J., and Goyal R.K. The columnar lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 110 (1996) 614-621
115. Shaheen N., and Ransohoff D.F. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. J Am Med Assoc 287 (2002) 1972-1981
116. Musana A.K., Resnick J.M., Torbey C.F., Mukesh B.N., and Greenlee R.T. Barrett's esophagus: incidence and prevalence estimates in a rural Mid-Western population. Am J Gastroenterol 103 (2008) 516-524
117. El-Serag H.B., Aguirre T.V., Davis S., Kuebeler M., Bhattacharyya A., and Sampliner R.E. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99 (2004) 1877-1883
118. Cooper B.T., Chapman W., Neumann C.S., and Gearty J.C. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 23 (2006) 727-733
119. Martinez S.D., Malagon I.B., Garewall H.S., Cui H., and Fass R. Non-erosive refluxdisease (NERD)-acid reflux and symptom patterns 17 (2003) 537-545
120. Sampliner R.E. Reduction of acid exposure and regression of Barrett's esophagus. Dig Dis 18 (2000-2001) 203-207
121. Richter J.E. Review article: extra-oesophageal manifestations of gastro-oesophageal disease. Aliment Pharmacol Ther 22 Suppl. 1 (2005) 70-80
122. Galmiche J.P., Zerbib F., and Bruley des Varannes S. Review article: respiratory manifestations of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 27 (2008) 449-464
123. Hogan W.J., and Shaker R. Medical treatment of supraesophageal complications of gastroesophageal reflux disease. Am J Med 111 Suppl. 8A (2001) 197S-201S
124. Richter J.E. Ear, nose and throat and respiratory manifestations of gastroesophageal reflux disease: an increasing conundrum. Eur J Gastroenterol Hepatol 16 (2004) 837-845
125. Qadeer M.A., Phillips C.O., Lopez A.R., Steward D.L., Noordzij J.P., Wo J.M., et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 (2006) 2646-2654
126. Gatta L., Vaira D., Sorrenti G., Zucchini S., Sama C., and Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther 25 (2007) 385-392
127. Sgouros S.N., and Mantides A. Refractory heartburn to proton pump inhibitors: epidemiology, aetiology and management. Digestion 73 (2006) 218-227
128. Fass R., Shapiro M., Dekel R., and Sewell J. Systematic review: proton pump inhibitor failure in gastro-oesophageal reflux disease-where next?. Aliment Pharmacol Ther 22 (2005) 79-94
129. Savarino V., Savarino E., and Dulbecco P. Proton pump inhibitor failure: why does it occur and how can it be managed. Digestion 73 (2006) 215-217
130. Gunaratnam N.T., Jessup T.P., Inadomi J., and Lascewski D.P. Sub-optimal proton pump inhbitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 23 (2006) 1473-1477
131. Pezanoski J., Guanaratnam N., and Cowen M. Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms. Gastroenterology 124 Suppl. (2003) A228
132. Chey W.D., Inadomi J.M., Booher A.M., Sharma V.K., Fendrick A.M., and Howden C.W. Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 100 (2005) 1237-1242
133. Frazzoni M., De Micheli E., Grisendi A., and Savarino V. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther 16 (2002) 881-886
134. Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 24 Suppl. 2 (2006) 10-16
135. Vaezi M.F., Singh S., and Richter J.E. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology 108 (1995) 1897-1907
136. Vela M., Camacho-Lobato L., Srinivasan R., Tutuian R., Katz P.O., and Castell D.O. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 120 (2001) 1599-1606
137. Mainie I., Tutuian R., Shay S., Vela M., Zhang X., Sifrim D., et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut 55 (2006) 1398-1402
138. Zerbib F., Roman S., Ropert A., des Varannes S.B., Pouderoux P., Chaput U., et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 101 (2006) 1956-1963
139. Karamanolis G., Vanuytsel T., Sifrim D., Bisschops R., Arts J., Caenepeel P., et al. Yield of 24-h esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 53 (2008) 2387-2393
140. Boeckxstaens G.E. Reflux inhibitors: a new approach for GERD?. Curr Opin Pharmacol 8 (2008) 685-689
141. Koek G.H., Sifrim D., Lerut T., Janssens J., and Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52 (2003) 1397-1402
142. Ros E., Pujol A., Bordas J.M., and Grande L. Efficacy of sucralfate in refractory reflux esophagitis. Results of a pilot study. Scand J Gastroenterol Suppl 24 Suppl. 156 (1989) 49-55
143. Scarpignato C. Sucralfate and other mucosal protective compounds: pharmacology and potential in the treatment of esophageal lesions. Front Gastrointest Res 20 (1992) 317-346
144. Richter J.E. Duodenogastric reflux-induced (alkaline) esophagitis. Curr Treat Options Gastroenterol 7 (2004) 53-58
145. Scarpignato C., and Franzé A. Esophageal exposure to acid in GERD patients with and without delayed gastric emptying. Effect of cisapride. Hepato-gastroenterology 39 (1992) 91-92
146. Scarpignato C., Micali B., and Galmiche J.P. Is delayed gastric emptying more frequent in GORD patients unresponsive to medical treatment?. Gut 37 Suppl. 2 (1995) A146
147. Scarpignato C., Pelosini I., and Galmiche J.P. Can a relationship be shown between persistent delayed gastric emptying and prevision of resistance to treatment and/or recurrence in patients treated for gastro-esophageal reflux?. In: Giuli R., et al. (Ed). The esophagogastric junction (1998), John Libbey Eurotext, Paris 693-701
148. Scarpignato C., and Pelosini I. Antisecretory drugs for eradication of Helicobacter pylori: antibacterial activity and synergism with antimicrobial agents. Prog Basic Clin Pharmacol 11 (1999) 135-178
149. Holtmann G., Cain C., and Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 117 (1999) 11-16
150. Schenk B.E., Kuipers E.J., Klinkenberg-Knol E.C., Eskes S.A., and Meuwissen S.G. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 94 (1999) 884-887
151. Leite L., Lambrecht N., Sachs G., Castell D., and Lagerstrom P. Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump?. Gastroenterology 108 (1995) A147
152. 2-receptor antagonists after omeprazole failure: report of two cases. Am J Gastroenterol 90 (1995) 1874-1877
153. Furuta T., Shirai N., Watanabe F., Honda S., Takeuchi K., Iida T., et al. Effect of the cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72 (2002) 453-460
154. Caraco Y., Wilkinson G.R., and Wood A.J. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 60 (1996) 396-404
155. Nzeako U.C., and Murray J.A. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 16 (2002) 1309-1316
156. Scarpignato C. Basic pathophysiology of upper gastrointestinal motility disorders. In: Braga P.C., Guslandi M., and Tittobello A. (Eds). Drugs in gastroenterology (1991), Raven Press, New York 3-20
157. Scarpignato C., Pelosini I., and Contini S. What is the effect of acid suppression with proton pump inhibitors on esophageal and gastric motility?. In: Giuli R., et al. (Ed). The duodenogastroesophageal reflux. 125 Questions, 125 Answers (2006), John Libbey Eurotext, Paris 262-271
158. Tytgat G.N., McColl K., Tack J., Holtmann G., Hunt R.H., Malfertheiner P., et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 27 (2008) 249-256
159. Shimatani T., Inoue M., Kuroiwa T., and Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 19 (2004) 113-122
160. Richter J.E. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 658-664
161. Wo J.M., Mendez C., Harrel S., Joubran R., Bressoud P.F., and McKinney W.P. Clinical impact of upper endoscopy in the management of patients with gastroesophageal reflux disease. Am J Gastroenterol 99 (2004) 2311-2316
162. Charbel S., Khanwala F., and Vaezi M.F. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 100 (2005) 283-289
163. ®). Gut 54 (2005) 1682-1686
164. Zentilin P., Dulbecco P., Savarino E., Giannini E., and Savarino V. Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastroesophageal reflux (literature review). Dig Liver Dis 36 (2004) 565-569
165. Mainie I., Tutuian R., Agrawal A., Adams D., and Castell D.O. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 93 (2006) 1483-1487
166. Becker V., Bajbouj M., Waller K., Schmid R.M., and Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors-a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther 26 (2007) 1355-1360
167. Berardi R.R. Proton pump inhibiton. An effective, safe approach to GERD management. Am J Manag Care 6 Suppl. (2000) S491-S505
168. Saigueiro E., Rubio T., Hidalgo A., and Manso G. Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions. Int J Clin Pharmacol Ther 44 (2006) 548-556
169. Garnett W.R. Considerations for long-term use of proton pump inhibitors. Am J Health Syst Pharm 55 (1998) 2249
170. Pounder R., and Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 19 (1990) 141-153
171. Laine L., Ahnen D., McClain C., Solcia E., and Walsh J.H. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14 (2000) 651-668
172. Klinkenberg-Knol E.C., Festen H.P., Jansen J.B., Lamers C.B., Nelis F., Snel P., et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 121 (1994) 161-167
173. Kuipers E.J., Uyterlinde A.M., Peña A.S., Hazenberg H.J., Bloemena E., Lindeman J., et al. Increase of Helicobacter pylori associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 90 (1995) 1402-1406
174. Sanduleanu S., Jonkers D., de Bruïne A., Hameeteman W., and Stockbrugger R.W. Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth. Dig Liver Dis 33 (2001) 707-719
175. Sanduleanu S., de Bruïne A., Stridsberg M., Jonkers D., Biemond I., Hameeteman W., et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 31 (2001) 802-811
176. Di Mario F., and Cavallaro L.G. Non-invasive test in gastric diseases. Dig Liver Dis 40 (2008) 523-530
177. Di Mario F., Ingegnoli A., Altavilla N., Cavallaro L.G., Bertolini S., Merli R., et al. Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels. Fundam Clin Pharmacol 19 (2005) 497-501
178. Freeman H.J. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol 14 (2008) 1318-1320
179. Yeomans N.D., and Dent J. Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid suppression?. Aliment Pharmacol Ther 14 (2000) 267-271
180. Nwokolo C., Loft D., Holder R., and Langman M. Increased incidence of bacterial diarrhoea in patients taking gastric acid antisecretory drugs. Eur J Gastroenterol Hepatol 6 (1994) 697-699
181. Neal K.R., Scott H.M., Slack R.C., and Logan R.F. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. Br Med J 312 (1996) 414-415
182. García Rodríguez L.A., Ruigómez A., and Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 5 (2007) 1418-1423
183. Leonard J., Marshall J.K., and Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102 (2007) 2047-2056
184. Choudhry M.N., Soran H., and Ziglam H.M. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. Q J Med 101 (2008) 445-448
185. Gulmez S.E., Holm A., Frederiksen H., Jensen T.G., Pedersen C., and Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 167 (2007) 950-955
186. Laheij R.J., Sturkenboom M.C., Hassing R.J., Dieleman J., Stricker B.H., and Jansen J.B. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. J Am Med Assoc 292 (2004) 1955-1960
187. Sarkar M., Hennessy S., and Yang Y.X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 149 (2008) 391-398
188. Gregor J.C. Acid suppression and pneumonia: a clinical indication for rational prescribing. J Am Med Assoc 292 (2004) 2012-2013
189. +-ATPase) expression in human laryngeal seromucinous glands. Otolaryngol Head Neck Surg 133 (2005) 718-724
190. Altman K.W., Waltonen J.D., Tarjan G., Radosevich J.A., and Haines III G.K. Human lung mucous glands manifest evidence of the H+/K+-ATPase proton pump. Ann Otol Rhinol Laryngol 116 (2007) 229-234
191. Saltzman J.R., Kowdley K.V., Pedrosa M.C., Sepe T., Golner B., Perrone G., et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology 106 (1994) 615-623
192. Larson A.M., Chan G.C., Wartelle C.F., McVicar J.P., Carithers Jr. R.L., Hamill G.M., et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 14 (1995) 364-368
193. Subbiah V., and Tayek J.A. Tetany secondary to the use of a proton-pump inhibitor. Ann Intern Med 137 (2002) 219
194. Epstein M., McGrath S., and Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 355 (2006) 1834-1836
195. 12 during prolonged omeprazole therapy. J Clin Gastroenterol 14 (1992) 288-292
196. 12). Ann Intern Med 120 (1994) 211-215
197. 12 status in elderly individuals. Aliment Pharmacol Ther 27 (2008) 491-497
198. 12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 27 (2008) 1110-1121
199. 12 deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 36 (2002) 812-816
200. Yeomans N.D., Brimblecombe R.W., Elder J., Heatley R.V., Misiewicz J.J., Northfield T.C., et al. Effects of acid suppression on microbial flora of upper gut. Dig Dis Sci 40 Suppl. 2 (1995) 81S-95S
201. Mirvish S.S. The etiology of gastric cancer: intragastric nitrosamide formation and other theories. J Natl Cancer Inst 71 (1983) 631-647
202. Forman D., Al Dabbagh S., and Doll R. Nitrates, nitrites and gastric cancer in Great Britain. Nature 313 (1985) 620-625
203. Mowat C., Williams C., Gillen D., Hossack M., Gilmour D., Carswell A., et al. Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-Nitrosation. Gastroenterology 119 (2000) 339-347
204. Myers R.P., McLaughlin K., and Hollomby D.J. Acute interstitial nephritis due to omeprazole. Am J Gastroenterol 96 (2001) 3428-3431
205. Geevasinga N., Coleman P.L., Webster A.C., and Roger S.D. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 4 (2006) 597-604
206. Balani A.R., and Grendell J.H. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf 31 (2008) 823-837
207. Youssef S.S., Iskandar S.B., Scruggs J., and Roy T.M. Acute pancreatitis associated with omeprazole. Int J Clin Pharmacol Ther 43 (2005) 558-561
208. Nørgaard M., Ratanajamit C., Jacobsen J., Skriver M.V., Pedersen L., and Sørensen H.T. Metronidazole and risk of acute pancreatitis: a population-based case-control study. Aliment Pharmacol Ther 21 (2005) 415-420
209. Cai J., Zhou W., Luo H.S., and Peng L.V. Effect of proton pump inhibitor on amylase release from isolated pancreatic acini. In Vitro Cell Dev Biol Anim 43 (2007) 25-27
210. Sundström A., Blomgren K., Alfredsson L., and Wiholm B.E. Acid-suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis-results from a Swedish Case-Control Study. Pharmacoepidemiol Drug Saf 15 (2006) 141-149
211. Eland I.A., Alvarez C.H., Stricker B.H., and Rodríguez L.A. The risk of acute pancreatitis associated with acid-suppressing drugs. Br J Clin Pharmacol 49 (2000) 473-478
212. Clark D.W., and Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?. Eur J Clin Pharmacol 62 (2006) 473-479
213. Thomson R.D., Lestina L.S., Bensen S.P., Toor A., Maheshwari Y., and Ratcliffe N.R. Lansoprazole-associated microscopic colitis: a case series. Am J Gastroenterol 97 (2002) 2908-2913
214. 2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79 (2006) 76-83
215. Yang Y.X., Lewis J.D., Epstein S., and Metz D.C. Long-term proton pump inhibitor therapy and risk of hip fracture. J Am Med Assoc 296 (2006) 2947-2953
216. Wright M.J., Proctor D.D., Insogna K.L., and Kerstetter J.E. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 66 (2008) 103-108
217. Targownik L.E., Lix L.M., Metge C.J., Prior H.J., Leung S., and Leslie W.D. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J 179 (2008) 319-326
218. Kaye J.A., and Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28 (2008) 951-959
219. Koh T.J., Dockray G.J., Varró A., Cahill R.J., Dangler C.A., Fox J.G., et al. Overexpression of glycine-extended gastrin in transgenic mice results in increased colonic proliferation. J Clin Invest 103 (1999) 1119-1126
220. -/+ mouse model of familial adenomatous polyposis. Cancer Res 61 (2001) 625-631
221. Yang Y.X., Hennessy S., Propert K., Hwang W.T., Sedarat A., and Lewis J.D. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133 (2007) 748-754
222. Robertson D.J., Larsson H., Friis S., Pedersen L., Baron J.A., and Sorensen H.T. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 133 (2007) 755-760
223. van Soest E.M., van Rossum L.G., Dieleman J.P., van Oijen M.G., Siersema P.D., Sturkenboom M.C., et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 103 (2008) 966-973
224. Lundell L., Miettinen P., Myrvold H.E., Hatlebakk J.G., Wallin L., Malm A., et al. Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. Br J Surg 94 (2007) 198-203
225. AstraZeneca Clinical Trials. Omeprazole versus anti-reflux surgery in the long-term management of reflux esophagitis: a 10-year follow up study of patients previously studied for 5 years-a Nordic multi-center study [http://www.astrazenecaclinicaltrials.com/Article/526660.aspx].
226. Lundell L., Attwood S., Ell C., Fiocca R., Galmiche J.P., Hatlebakk J., et al. Comparing laparoscopic anti-reflux surgery to esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 57 (2008) 1207-1213
227. ® (esomeprazole)-early communication about an ongoing safety review [http://pharmalive.com/news/index.cfm?articleID=466520&categoryid=43].
228. Humphries T.J., and Merritt G.J. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 13 Suppl. 3 (1999) 18-26
229. McCarthy D.M., McLaughlin T., Yazdani C., El Serag H.B., and Griffis D.L. Effects of co-therapy with early proton pump inhibitors (PPIs) on the occurrence of side effects of other drugs with potential for interaction with PPIs: a cohort study. Gastroenterology 122 Suppl. 1 (2002) A210
230. Labenz J., Petersen K.U., Rosch W., and Koelz H.R. A summary of food and drug administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 17 (2003) 1015-1059
231. Steinijans V.W., Huber R., Hartmann M., Zech K., Bliesath H., Wurst W., et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 34 (1996) 243-262
232. Fuhr U., and Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 57 (2002) 595-601
233. Giannini E.G., Savarino V., and Testa R. Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease. Dig Dis Sci 51 (2006) 1602-1606
234. Takahashi K., Yano I., Fukuhara Y., Katsura T., Takahashi T., Ito N., et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet 22 (2007) 441-444
235. Hosohata K., Masuda S., Ogura Y., Oike F., Takada Y., Katsura T., et al. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet 23 (2008) 134-138
236. Richter J.E. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther 22 (2005) 749-757
237. Lalkin A., Loebstein R., Addis A., Ramezani-Namin F., Mastroiacovo P., Mazzone T., et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 179 (1998) 727-730
238. Nikfar S., Abdollahi M., Moretti M.E., Magee L.A., and Koren G. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 47 (2002) 1526-1529
239. Diav-Citrin O., Arnon J., Shechtman S., Schaefer C., van Tonningen M.R., Clementi M., et al. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 21 (2005) 269-275
240. Zimmermann A.E., Walters J.K., Katona B.G., Souney P.E., and Levine D. A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther 23 (2001) 660-679
241. Croom K.F., and Scott L.J. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents. Drugs 65 (2005) 2129-2135
242. Tsou V.M., Baker R., Book L., Hammo A.H., Soffer E.F., Wang W., et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr 45 (2006) 741-749
243. James L., Walson P., Lomax K., Kao R., Varughese S., and Reyes J. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. Clin Ther 29 (2007) 2082-2092
244. Gilger M.A., Tolia V., Vandenplas Y., Youssef N.N., Traxler B., and Illueca M. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 46 (2008) 524-533
245. Hassall E., Kerr W., and El-Serag H.B. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 150 (2007) 262-267
246. Tolia V., and Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 53 (2008) 385-393
247. Tytgat G.N. Are there unmet needs in acid suppression?. Best Pract Res Clin Gastroenterol 18 Suppl. (2004) 67-72
248. Hunt R.H. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 22 Suppl. 3 (2005) 10-19
249. Scarpignato C., Pelosini I., and Di Mario F. Acid suppression therapy: where do we go from here?. Dig Dis 24 (2006) 11-46